Syngene International and Bristol Myers Squibb Extend Partnership Until 2035

Syngene International Expands Collaboration with Bristol Myers Squibb

Syngene International, a prominent global contract research, development, and manufacturing organization (CRDMO), recently announced the extension of its strategic alliance with Bristol Myers Squibb (BMS) until 2035. This move is a significant enhancement to a partnership that has thrived for over 25 years, underscoring Syngene's commitment to providing comprehensive services throughout the drug development cycle.

The collaboration covers a broad range of integrated services, including discovery (encompassing chemistry, biology, drug metabolism, and pharmacokinetics), translational sciences, pharmaceutical development, manufacturing, clinical trials, and IT services. This expansion aims to facilitate a more seamless transition from research to commercial applications, highlighting Syngene's role as a vital partner in advancing medical innovations.

Peter Bains, CEO of Syngene International, expressed his enthusiasm about the extension, stating, “Our collaboration with BMS is rooted in scientific excellence and a shared commitment to transforming therapy development. This agreement allows us to strategically plan for future capabilities and infrastructure.” Bains also noted the importance of long-term vision in strengthening both companies' strategic objectives, further enhancing their joint efforts towards new discoveries and therapies that can significantly impact patient outcomes globally.

Payal Sheth, Senior VP of Therapeutic Discovery Sciences at BMS, echoed these sentiments, stating, “Our partnership with Syngene has been crucial in nurturing our scientific goals. By expanding this collaboration, we are better positioned to merge our research, development, and manufacturing capabilities to expedite the delivery of groundbreaking medicines.”

The roots of the partnership trace back to 1998 with the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC) in India. Officially inaugurated in 2009, the BBRC has since evolved into one of BMS's central research sites. The facility provides integrated capabilities across various fields, including target identification, lead discovery, pharmacological development, and clinical biomarker research. Presently, around 700 Syngene scientists operate at BBRC, reinforcing BMS's global research efforts across various therapeutic areas, including cardiovascular diseases, fibrosis, immunology, and oncology.

BBRC has significantly contributed to advancing new compounds from early discovery stages to the first-in-human trials, streamlining development processes while reducing costs for BMS. This is imperative for the pharmaceutical industry, which is under consistent pressure to deliver effective treatments efficiently and economically.

Syngene International currently employs over 8,200 team members, including approximately 5,600 scientists. The company's capabilities span various sectors, including pharmaceuticals, biotechnology, nutrition, animal health, and specialty chemicals. With more than 2.5 million square feet of specialized facilities across the United States and India, Syngene caters to around 400 global customers, including notable pharmaceutical companies like BMS, GSK, and Merck KGaA.

In summary, the extended collaboration between Syngene International and Bristol Myers Squibb marks a critical step forward in drug development, emphasizing shared values of scientific progress and innovation. It showcases a mutual commitment to improving patient health outcomes worldwide and sets a strong foundation for future scientific breakthroughs.